Trial Profile

PHASE II STUDY OF CLOFARABINE IN COMBINATION WITH CYTARABINE AND LIPOSOMAL DOXORUBICIN IN CHILDREN WITH EITHER LYMPHOBLASTIC OR MYELOID RELAPSE OR REFRACTORY ACUTE LEUKEMIA AND IN CHILDREN WITH SECONDARY ACUTE MYELOID LEUKEMIA STUDIO DI FASE II SULL'UTILIZZO DI CLOFARABINA IN COMBINAZIONE CON CITARABINA E DOXORUBICINA LIPOSOMIALE IN PAZIENTI PEDIATRICI CON DIAGNOSI DI LEUCEMIA LINFOBLASTICA ACUTA E LEUCEMIA MIELOIDE ACUTA IN RECIDIVA O REFRATTARIA O DI LEUCEMIA MIELOIDE ACUTA SECONDARIA

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clofarabine (Primary) ; Cytarabine; Doxorubicin liposomal
Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Acronyms CLA-MYOCET

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com